Prophylactic human papillomavirus vaccines: Past, present and future

Pathology

Volumn 44, Issue 1, 2012, Pages 1-6

  Anderson, Lyndal A ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Bivalent; Capsid; Cervical carcinoma; Episomes; Human Papillomavirus; Immunisation; Mandatory vaccination; Neutralising antibodies; Quadrivalent; Virions; Virus like particles

Indexed keywords

EID: 84858179086     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834d7bd8     Document Type: Article

References (63)

1. Kahn JA, Burk RD. Papillomavirus vaccines in perspective. Lancet 2007; 369: 2135-7.
2. World Health Organization. Human papillomavirus vaccines: WHO position paper. Biologicals 2009; 37: 338-44.
3. Frazer IH. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol 2010; 118: S8-11.
4. Arie S. Global HPV vaccination. BMJ 2011; 342: D1042.
5. Australian Institute of Health and Welfare. Australia's Health 2010. Australia's Health Series no. 12. Cat no. AUS122. Canberra: Australian Institute of Health and Welfare, 2010.
6. Garland SM. Prevention strategies against human papillomavirus in males. Gynecol Oncol 2010; 117: S20-5.
7. zur Hausen H, de Villiers EM, Gissmann L. Papillomavirus infections and human genital cancer. Gynecol Oncol 1981; 12: S124-8. (Pubitemid 12249694)
8. zur Hausen H. The search for infectious causes of human cancers: Where and why (Nobel lecture). Angew Chem Int Ed Engl 2009; 48: 5798-808.
9. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nature Rev Immunol 2004; 4: 46-54. (Pubitemid 38084131)
10. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907. (Pubitemid 47371147)
11. Palmer KE, Jenson AB, Kouokam JC, Lasnik AB, Ghim S-J. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer. Exp Mol Pathol 2009; 86: 224-33.
12. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78: 11451-60. (Pubitemid 39390733)
13. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-62. (Pubitemid 38240914)
14. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396: 84-8. (Pubitemid 28520454)
15. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79-82. (Pubitemid 26076241)
16. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994; 8: 666-77. (Pubitemid 24116761)
17. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004; 64: 3878-84. (Pubitemid 38697299)
18. Duensing S, Duensing A, Flores ER, Do A, Lambert PF, Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol 2001; 75: 7712-6. (Pubitemid 32738029)
19. Hafner N, Driesch C, Gajda M, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008; 27: 1610-7. (Pubitemid 351347875)
20. Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ. HPV-DNA integration and carcinogenesis: Putative roles for inflammation and oxidative stress. Future Virol 2011; 6: 45-57.
21. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006; 24 (Suppl 3): S3/106-13.
22. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl 1): S16-22.
23. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 14-9.
24. Wikstrom A, van Doornum GJ, Kirnbauer R, Quint WG, Dillner J. Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol 1995; 46: 368-74.
25. Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 1992; 190: 548-52.
26. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-7.
27. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89: 12180-4.
28. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles. J Virol 1993; 67: 1936-44. (Pubitemid 23088366)
29. Hofmann KJ, Cook JC, Joyce JG, et al. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 1995; 209: 506-18.
30. Jansen KU, Rosolowsky M, Schultz LD, et al. Vaccination with yeastexpressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995; 13: 1509-14.
31. Cho HJ, Oh YK, Kim YB. Advances in human papilloma virus vaccines: A patent review. Exp Opin Ther Patents 2011; 21: 295-309.
32. McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst 2006; 98: 433.
33. Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S. Intellectual property, technology transfer andmanufacture of low-cost HPV vaccines in India. Nat Biotechnol 2010; 28: 671-8.
34. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37: 3316-22. (Pubitemid 29455226)
35. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007; 298: 743-53. (Pubitemid 47263157)
36. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
37. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.
38. Erratum in Obstet Gynecol 2006 107:1425
39. Villa LL, Perez G, Kjaer SK, et al. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196: 1438-46. (Pubitemid 351411978)
40. Ault KA. Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8. (Pubitemid 46829356)
41. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70. (Pubitemid 46977438)
42. Erratum in Lancet 2007 370:1414
43. Kane MA. Global implementation of human papillomavirus (HPV) vaccine: Lessons from hepatitis B vaccine. Gynecol Oncol 2010; 117: S32-5.
44. Frazer IH. The two faces of human papillomavirus. Gynecol Oncol 2010; 117: S4.
45. Dempsey A, Cohn L, Dalton V, Ruffin M. Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine 2011; 29: 528-34.
46. Rana M, Paavonen J, Apter DL, Luostarinen T, Pukkala E, Lehtinen MO. Long-term efficacy of human papillomavirus vaccination against hard endpoints: Cancer registry-based follow-up of phase 3 efficacy trials (PATRICIA). European Research Organization on Genital Infection and Neoplasia (Eurogin) Congress, Lisbon, 2011. Abstract presentation.
47. Kjaer SK. An evaluation for the long-term effectiveness, immunogenicity and safety of GardasilTM in previously vaccinated women. European Research Organization on Genital Infection and Neoplasia (Eurogin) Congress, Lisbon, 2011. Abstract presentation.
48. Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 2011; 377: 2085-92.
49. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey - Adult 2007. Prev Med 2009; 48: 426-31.
50. Wong L-P. Knowledge of and attitudes toward the HPV vaccine among multi-ethnic women from urban/university and rural areas. Int J Gynaecol Obstet 2011; 112: 146-7.
51. Kahan DM, Braman D, Cohen GL, Gastil J, Slovic P. Who fears the HPV vaccine, who doesn't, and why? An experimental study of the mechanisms of cultural cognition. Law Hum Behav 2010; 34: 501-16.
52. Faunce T, Townsend R, McEwan A. The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe &Dohme (Aust) Pty Ltd (2010) 184 FCR 1. J Law Med 2010; 18: 38-49.
53. Hildesheim A, Markowitz L, Avila MH, Franceschi S. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Vaccine 2006; 24 (Suppl 3): S3/227-32.
54. Jagu S, Kwak K, Garcea RL, Roden RBS. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 2010; 28: 4478-86.
55. Heffernan CB, O'Neill JP, Timon C. Oncogenic impact of human papilloma virus in head and neck cancer. J Laryngol Otol 2010; 124: 941-4.
56. Nurkkala M, Wassen L, Nordstrom I, et al. Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia. Vaccine 2010; 28: 5828-36.
57. Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol 2009; 10: 975-80.
58. Giles M, Garland S. Human papillomavirus infection: An old disease, a new vaccine. Aust NZ J Obstet Gynaecol 2006; 46: 180-5. (Pubitemid 44056722)
59. Markman M. Human papillomavirus vaccines to prevent cervical cancer. Lancet 2007; 369: 1837-9. (Pubitemid 46829342)
60. Franceschi S, Denny L, Irwin KL, et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011; 128: 2765-74.
61. Goodman A, Wilbur DC. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2003.
62. A 37-year-old woman with atypical squamous cells on a Papanicolaou smear. N Engl J Med 2003; 349: 1555-64.
63. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006; 110: 525-41. (Pubitemid 43736116)